Comparative Pharmacology
Head-to-head clinical analysis: RIFAXIMIN versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIFAXIMIN versus SATRIC.
RIFAXIMIN vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rifaximin is a non-aminoglycoside, semi-synthetic antibiotic derived from rifamycin that inhibits bacterial RNA synthesis by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby blocking transcription.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
550 mg orally three times daily for 14 days for travelers' diarrhea; 200 mg orally three times daily for 3 days for irritable bowel syndrome with diarrhea; 400 mg orally three times daily for 7 days for hepatic encephalopathy.
No standard dosing information available for SATRIC.
None Documented
None Documented
Clinical Note
moderateRifaximin + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Rifaximin."
Clinical Note
moderateRifaximin + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Rifaximin."
Clinical Note
moderateRifaximin + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Rifaximin."
Clinical Note
moderateRifaximin + Tranilast
The terminal elimination half-life is approximately 1.8 to 2.5 hours in patients with normal hepatic function. Due to negligible systemic absorption, the half-life has limited clinical relevance; drug action is largely confined to the gastrointestinal tract.
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Rifaximin is primarily eliminated in feces as unchanged drug (>96% of an oral dose). Renal excretion is negligible (<0.4%). Biliary excretion is minimal due to poor systemic absorption.
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category A/B
Category C
Antibiotic
Antiprotozoal, Antibiotic
"The serum concentration of Tranilast can be decreased when it is combined with Rifaximin."